171 Discussion and future perspectives 15. NCI-MATCH Sets “Benchmark of Actionability”. Cancer Discov 2021;11(1):6-7. DOI: 10.1158/21598290.CD-NB2020-100. 16. Mangat PK, Halabi S, Bruinooge SS, et al. Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. Jco Precis Oncol 2018;2:1-14. (In English). DOI: 10.1200/Po.18.00122. 17. Halabi SM, P.; Garrett-Mayer, E.; van der Wijngaart, H.; Verheul, H.M.W.; Voest, E.E.; Siu, L.; Renouf, D.J.; Dancey, J.; Schilsky, R.L. Advancing Precision Oncology: TADRUCA, A Model for Global Collaboration. 18. Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. International Journal of Cancer 2023 (In English). DOI: 10.1002/ijc.34649. 19. Hoes LR, Henegouwen JMV, van der Wijngaart H, et al. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. Clinical Cancer Research 2022;28(7):1402-1411. (In English). DOI: 10.1158/1078-0432.Ccr-21-3752. 20. Mock A, Heilig CE, Kreutzfeldt S, Gonzalez-Carmona MA. Community-driven development of a modified progression-free survival ratio for precision oncology (vol 4, e000583, 2019). Esmo Open 2020;5(1) (In English). DOI: ARTN e000583corr1 10.1136/esmoopen-2019-000583corr1. 21. Wu JR, Chen L, Wei J, Weiss H, Miller RW, Villano JL. Phase II trial design with growth modulation index as the primary endpoint. Pharm Stat 2019;18(2):212-222. (In English). DOI: 10.1002/pst.1916. 22. Basse C, Morel C, Alt M, et al. Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie. Esmo Open 2018;3(3) (In English). DOI: UNSP e000339 10.1136/esmoopen-2018-000339. 23. van de Haar J, Hoes L, Voest E. Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine. Esmo Open 2019;4(2) (In English). DOI: UNSP e000516 10.1136/ esmoopen-2019-000516. 24. van der Velden DL, van Herpen CML, van Laarhoven HWM, et al. Molecular Tumor Boards: current practice and future needs. Ann Oncol 2017;28(12):3070-3075. (In English). DOI: 10.1093/annonc/ mdx528. 25. Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. Nature Medicine 2022;28(4):658-665. (In English). DOI: 10.1038/s41591-022-01717-2. 26. Jonsson P, Bandlamudi C, Cheng ML, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature 2019;571(7766):576-579. DOI: 10.1038/s41586-019-1382-1. 27. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research 2010;16(8):23442351. (In English). DOI: 10.1158/1078-0432.Ccr-09-2758. 28. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451(7182):1116-U9. (In English). DOI: 10.1038/nature06633. 6
RkJQdWJsaXNoZXIy MTk4NDMw